Compare Neurocrine Biosciences Inc (NBIX) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vanguard Growth Index Fund ETF — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Vanguard Growth Index Fund ETF trades at $86.11. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Vanguard Growth Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | VUG | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | Sector/Thematic |
52-Week High | $180.55 | $90.29 |
52-Week Low | $123.10 | $70.00 |
Enterprise Value | $16.49B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
